Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
Website:
http://www.artivabio.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Tue, 10 Sep 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
ARTV Latest News
Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indications Treated first patient in Artiva sponsored Phase 1/1b trial in patients with class III or IV lupus nephritis (LN) and expanded trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent progress. “Artiva is at an inflection point as we advance AlloNK® in clinical development across multiple autoimmune indications and transition to a publicly traded company,” said Fred Aslan, M.D.
Artiva has two-bagger potential in the eyes of multiple Wall Street analysts. Its cell therapies could provide a much more efficient treatment of autoimmune diseases.
In July, Artiva Biotherapeutics, Inc. ARTV priced its upsized initial public offering of 13.92 million shares at $12.00 per share, with gross proceeds of approximately $167.0 million.
24/7 Wall St. Insights In the past week or so, initial public offerings at a biotech and an investment management firm attracted huge insider buying.
What type of business is Artiva Biotherapeutics Common Stock?
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
What sector is Artiva Biotherapeutics Common Stock in?
Artiva Biotherapeutics Common Stock is in the Healthcare sector
What industry is Artiva Biotherapeutics Common Stock in?
Artiva Biotherapeutics Common Stock is in the Biotechnology industry
What country is Artiva Biotherapeutics Common Stock from?
Artiva Biotherapeutics Common Stock is headquartered in United States
What is Artiva Biotherapeutics Common Stock website?
https://www.artivabio.com
Is Artiva Biotherapeutics Common Stock in the S&P 500?
No, Artiva Biotherapeutics Common Stock is not included in the S&P 500 index
Is Artiva Biotherapeutics Common Stock in the NASDAQ 100?
No, Artiva Biotherapeutics Common Stock is not included in the NASDAQ 100 index
Is Artiva Biotherapeutics Common Stock in the Dow Jones?
No, Artiva Biotherapeutics Common Stock is not included in the Dow Jones index
When was Artiva Biotherapeutics Common Stock the previous earnings report?
No data
When does Artiva Biotherapeutics Common Stock earnings report?
Next earnings report date is not announced yet